|
Press Releases
The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival
In the NRG Oncology clinical trial NRG-RTOG 1112, which sought to better determine the role of stereotactic body radiation therapy (SBRT) in the treatment of patients with advanced hepatocellular carcinoma (HCC), it was demonstrated that adding SBRT to Sorafenib improved overall survival (OS). These results were presented during the Plenary Session of the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in October 2022. NRG Oncology designed and led this trial which was conducted in the National Clinical Trials Network with funding from the National Cancer Institute, part of the National Institutes of Health.
Read the full press release
Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard
NRG Oncology investigators analyzed clinical and digital histopathology data from five Phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multi-modal intelligence models (MMAI) that could outperform the National Comprehensive Cancer Network (NCCN) in the prediction of distant metastasis (DM) and other outcomes. MMAI models could, in fact, stratify patients into risk groups that more accurately reflected their prognosis in comparison to NCCN risk groups. These results were presented during the Plenary Session of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2022.
Read the full press release
Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer
Results from the analysis of the NRG Oncology RTOG 1005 clinical trial data concluded that treating patients with early-stage, high-risk breast cancer with a supplemental radiation boost to the surgical cavity concurrently during hypo-fractionated whole breast irradiation (H-WBI) for a 3-week treatment course was not considered inferior to treating patients over several weeks with conventional whole breast irradiation (C-WBI) and a sequential boost following lumpectomy. These results were recently presented during the Plenary Session of the American Society for Radiation Oncology (ASTRO) Annual Meeting in October 2022.
Read the full press release
NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research
The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional failure (LRF) when compared to RT + cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) that have a contraindication to cisplatin. These findings were presented during the plenary session at American Society for Radiation Oncology (ASTRO) annual meeting held in San Antonio, Texas. This was one of four NRG Oncology papers presented during the 2022 ASTRO plenary session.
Read the full press release
Toxicity Data Reveal No Safety Concerns with S/N1806 Bladder Cancer Trial
Updated toxicity data from the ongoing SWOG/NRG 1806 clinical trial, which tests combining chemoradiation therapy with immunotherapy in patients with localized muscle-invasive bladder cancer, reveal no significant safety concerns with the combination.
Read the full press release
| 
